Trial intelligence / Profile preview

Indacaterol crossover study in moderate-to-severe COPD during endurance exercise

2008-008748-26Phase 3Completed

Sponsor
Novartis
Start
Mar 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Exercise endurance time after 3 weeks. Started Mar 2009; status: completed.

02

Drugs

indacaterol
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on 2008-008748-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-008748-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call